Byrne Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-100
| Closed | -$930 | – | 537 |
|
|
2024
Q3 | $930 | Hold |
100
| – | – | ﹤0.01% | 520 |
|
|
2024
Q2 | $942 | Hold |
100
| – | – | ﹤0.01% | 521 |
|
|
2024
Q1 | $991 | Hold |
100
| – | – | ﹤0.01% | 515 |
|
|
2023
Q4 | $302 | Hold |
100
| – | – | ﹤0.01% | 533 |
|
|
2023
Q3 | $1K | Hold |
100
| – | – | ﹤0.01% | 498 |
|
|
2023
Q2 | $1K | Sell |
100
-100
| -50% | -$1K | ﹤0.01% | 569 |
|
|
2023
Q1 | $2K | Hold |
200
| – | – | ﹤0.01% | 540 |
|
|
2022
Q4 | $2.96K | Hold |
200
| – | – | ﹤0.01% | 472 |
|
|
2022
Q3 | $4K | Hold |
200
| – | – | ﹤0.01% | 419 |
|
|
2022
Q2 | $4K | Hold |
200
| – | – | ﹤0.01% | 437 |
|
|
2022
Q1 | $4K | Buy |
200
+150
| +300% | +$3K | ﹤0.01% | 458 |
|
|
2021
Q4 | $1K | Buy |
+50
| New | +$1K | ﹤0.01% | 514 |
|